Verismo Therapeutics
Biotechnology Research • 
Philadelphia, Pennsylvania, United States • 21-50 Employees
Company overview
| Headquarters | 3675 Market St, Suite 200, Philadelphia, Pennsylvania 19104, US |
| Phone number | +12159894225 |
| Website | |
| NAICS | 541714 |
| Keywords | Cell Therapy, Immuno-Oncology, Car-T, Solid Tumor, Kir-Car Platform |
| Founded | 2020 |
| Employees | 21-50 |
| Socials |
Key Contacts at Verismo Therapeutics
Raymond Luke
Senior Director Of Msat, Head Of Cmc
Michael Milone
Founder
Pavel Aprelev
Director Of Corporate Development / Start-Up Member
Emily Winters
Associate Director Clinical Operations
Jacqueline Stief
Executive Director Quality And Compliance
Jun Xu. Ph D.
Executive Director Of Translational Science
Verismo Therapeutics Email Formats
Verismo Therapeutics uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@verismotherapeutics.com), used 52% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@verismotherapeutics.com | 52% |
{first name}.{last name} | john.doe@verismotherapeutics.com | 40% |
{first initial}.{second initial} | j.o@verismotherapeutics.com | 8% |
About Verismo Therapeutics
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Verismo Therapeutics revenue & valuation
| Annual revenue | $2,566,650 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $8,300,000 |
| Total funding | $21,150,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Verismo Therapeutics has 13 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Verismo Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Verismo Therapeutics Tech Stack
Discover the technologies and tools that power Verismo Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Form builders
JavaScript libraries
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Miscellaneous
Security
Programming languages
Blogs
Analytics
Netherlands
Spain
Frequently asked questions
4.8
40,000 users
